Media
Pharma in Focus
Blood cancer trial astounds again
Proactive Investors
Imugene secures $22.5 million placement and launches $15 million SPP to fund azer-cel trial
Money News Podcast
Leslie Chong, Imugene CEO
BioWorld
Imugene’s allogeneic CD19 CAR T sees 75% response rate
Biotech Dispatch
Imugene reports two additional complete responses in azer-cel CAR T Phase 1b trial
Proactive Investors
Imugene trial: 75% response rate in diffuse large B-cell lymphoma
Proactive Investors
Imugene’s azer-cel shows strong results in Phase 1b trial for DLBCL, set for FDA meeting
Proactive Investors
Imugene doses first patient in Australia for PD1-Vaxx Neo-POLEM Phase II trial
BiotechDispatch
Imugene announces US patent allowance for onCARlytics
Proactive Investors
Imugene secures core US patent for onCARlytics virotherapy platform
Proactive Investors
Imugene CMO and CEO talk trial momentum and immuno-oncology progress
Proactive Investors